SPARCL1 and Alzheimer disease: Furthermore, earlier investigations have provided evidence that SPARC exhibits high expression levels in the brain affected by AD and co‐localizes with Aβ protein deposits, while it has been proposed that Hevin may undergo downregulation in the diseased state (Singh et al. 2016).